Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
- 18 September 2012
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet Oncology
- Vol. 13 (10), 1020-1024
- https://doi.org/10.1016/s1470-2045(12)70373-x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor–induced pruritusJournal of the American Academy of Dermatology, 2010
- Aprepitant against pruritus in patients with solid tumoursSupportive Care in Cancer, 2010
- Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic StrategyPLOS ONE, 2010
- Aprepitant as an Antipruritic Agent?New England Journal of Medicine, 2009
- Neuropeptides and their receptors in psoriatic skin in relation to pruritusBritish Journal of Dermatology, 2007
- Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical ManagementThe Oncologist, 2007
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006
- Neuroanatomy and neurophysiology of itchDermatologic Therapy, 2005
- Topical anti-itch therapyDermatologic Therapy, 2005